Skip to main navigation Skip to search Skip to main content

A phase II trial (ago 2.11) in platinum-resistant ovarian cancer: A randomized multicenter trial with sunitinib (su11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy

K. H. Baumann, A. Du Bois, W. Meier, J. Rau, P. Wimberger, J. Sehouli, C. Kurzeder, F. Hilpert, A. Hasenburg, U. Canzler, L. C. Hanker, P. Hillemanns, B. Richter, K. Wollschlaeger, T. Dewitz, D. Bauerschlag, U. Wagner

78   Link opens in a new tab Citations (Scopus)

Fingerprint

Dive into the research topics of 'A phase II trial (ago 2.11) in platinum-resistant ovarian cancer: A randomized multicenter trial with sunitinib (su11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy'. Together they form a unique fingerprint.
Sort by

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science